For immediate release -- 1 of 22 -- -- 2 of 22 -- 3.2% – 3.7% / 3.5% 2.0% – 3.0% / 2.5% $92.7B – $93.1B / $92.9B 4.5% – 5.0% / 4.8% $91.6B – $92.4B / $92.0B 3.3% – 4.3% / 3.8% $93.2B – $93.6B / $93.4B 5.1% – 5.6% / 5.4% $91.0B – $91.8B / $91.4B 2.6% – 3.6% / 3.1% $10.63 – $10.73 / $10.68 6.5% – 7.5% / 7.0% $10.50 – $10.70 / $10.60 5.2% – 7.2% / 6.2% $10.80 – $10.90 / $10.85 8.2% – 9.2% / 8.7% $10.50 – $10.70 / $10.60 5.2% – 7.2% / 6.2% -- 3 of 22 -- -- 4 of 22 -- . -- 5 of 22 -- -- 6 of 22 -- Johnson & Johnson and Subsidiaries Supplementary Sales Data (Unaudited; Dollars in Millions) Percent Change 2025 2024 Total Operations Currency 2025 2024 Total Operations Currency Sales to customers by segment of business Innovative Medicine U.S. 9,161 $ 8,510 7.6 % 7.6 - 17,253 $ 16,122 7.0 % 7.0 - International 6,041 5,980 1.0 (1.6) 2.6 11,822 11,930 (0.9) (0.1) (0.8) 15,202 14,490 4.9 3.8 1.1 29,075 28,052 3.6 4.0 (0.4) MedTech U.S. 4,383 4,059 8.0 8.0 - 8,596 8,067 6.6 6.6 - International 4,158 3,898 6.7 4.1 2.6 7,965 7,711 3.3 3.6 (0.3) 8,541 7,957 7.3 6.1 1.2 16,561 15,778 5.0 5.1 (0.1) U.S. 13,544 12,569 7.8 7.8 - 25,849 24,189 6.9 6.9 - International 10,199 9,878 3.2 0.6 2.6 19,787 19,641 0.7 1.4 (0.7) Worldwide 23,743 $ 22,447 5.8 % 4.6 1.2 45,636 $ 43,830 4.1 % 4.4 (0.3) Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely. SECOND QUARTER SIX MONTHS Percent Change -- 7 of 22 -- Johnson & Johnson and Subsidiaries Supplementary Sales Data (Unaudited; Dollars in Millions) Percent Change 2025 2024 Total Operations Currency 2025 2024 Total Operations Currency Sales to customers by geographic area U.S. 13,544 $ 12,569 7.8 % 7.8 - 25,849 $ 24,189 6.9 % 6.9 - Europe 5,387 5,214 3.3 (1.9) 5.2 10,497 10,377 1.1 0.2 0.9 Western Hemisphere excluding U.S. 1,206 1,212 (0.5) 6.2 (6.7) 2,373 2,406 (1.3) 7.7 (9.0) Asia-Pacific, Africa 3,606 3,452 4.4 2.4 2.0 6,917 6,858 0.9 0.9 0.0 International 10,199 9,878 3.2 0.6 2.6 19,787 19,641 0.7 1.4 (0.7) Worldwide 23,743 $ 22,447 5.8 % 4.6 1.2 45,636 $ 43,830 4.1 % 4.4 (0.3) Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely. SECOND QUARTER SIX MONTHS Percent Change -- 8 of 22 -- Johnson & Johnson and Subsidiaries Condensed Consolidated Statement of Earnings (Unaudited; in Millions Except Per Share Figures) Percent Percent Percent Increase Amount to Sales Amount to Sales (Decrease) Sales to customers 23,743 $ 100.0 22,447 $ 100.0 5.8 Cost of products sold 7,628 32.1 6,869 30.6 11.0 Gross Profit 16,115 67.9 15,578 69.4 3.4 Selling, marketing and administrative expenses 5,889 24.8 5,681 25.3 3.7 Research and development expense 3,516 14.8 3,440 15.3 2.2 In-process research and development impairments - - 194 0.9 Interest (income) expense, net 48 0.2 (125) (0.6) Other (income) expense, net 107 0.5 653 2.9 Restructuring 64 0.3 (13) 0.0 Earnings before provision for taxes on income 6,491 27.3 5,748 25.6 12.9 Provision for taxes on income 954 4.0 1,062 4.7 (10.2) Net earnings 5,537 $ 23.3 4,686 $ 20.9 18.2 Net earnings per share (Diluted) 2.29 $ 1.93 $ 18.7 Average shares outstanding (Diluted) 2,419.1 2,422.0 Effective tax rate 14.7 % 18.5 % Adjusted earnings before provision for taxes and net earnings (1) Earnings before provision for taxes on income 8,188 $ 34.5 8,404 $ 37.4 (2.6) Net earnings 6,699 $ 28.2 6,840 $ 30.5 (2.1) Net earnings per share (Diluted) 2.77 $ 2.82 $ (1.8) Effective tax rate 18.2 % 18.6 % (1) See Reconciliation of Non-GAAP Financial Measures. SECOND QUARTER 2025 2024 -- 9 of 22 -- Johnson & Johnson and Subsidiaries Condensed Consolidated Statement of Earnings (Unaudited; in Millions Except Per Share Figures) Percent Percent Percent Increase Amount to Sales Amount to Sales (Decrease) Sales to customers 45,636 $ 100.0 43,830 $ 100.0 4.1 Cost of products sold 14,985 32.8 13,380 30.5 12.0 Gross Profit 30,651 67.2 30,450 69.5 0.7 Selling, marketing and administrative expenses 11,001 24.1 10,938 25.0 0.6 Research and development expense 6,741 14.8 6,982 16.0 (3.5) In-process research and development impairments - - 194 0.4 Interest (income) expense, net (80) (0.2) (334) (0.8) Other (income) expense, net (7,214) (15.8) 3,057 7.0 Restructuring 81 0.2 151 0.3 Earnings before provision for taxes on income 20,122 44.1 9,462 21.6 112.7 Provision for taxes on income 3,586 7.9 1,521 3.5 135.8 Net earnings 16,536 $ 36.2 7,941 $ 18.1 108.2 Net earnings per share (Diluted) 6.82 $ 3.27 $ 108.6 Average shares outstanding (Diluted) 2,423.3 2,428.5 Effective tax rate 17.8 % 16.1 % Adjusted earnings before provision for taxes and net earnings (1) Earnings before provision for taxes on income 16,199 $ 35.5 16,281 $ 37.1 (0.5) Net earnings 13,405 $ 29.4 13,420 $ 30.6 (0.1) Net earnings per share (Diluted) 5.53 $ 5.53 $ 0.0 Effective tax rate 17.2 % 17.6 % (1) See Reconciliation of Non-GAAP Financial Measures. SIX MONTHS 2025 2024 -- 10 of 22 -- Johnson & Johnson and Subsidiaries Reconciliation of Non-GAAP Financial Measures (Dollars in Millions Except Per Share Data) 2025 2024 2025 2024 Net Earnings, after tax- as reported $5,537 $4,686 $16,536 $7,941 Pre-tax Adjustments Litigation related 57 352 (6,909) 3,078 Intangible Asset Amortization expense 1,267 1,106 2,387 2,184 COVID-19 Vaccine related costs - 64 - 73 Restructuring related 1 79 (11) 134 160 Medical Device Regulation - 68 - 119 Acquisition, integration and divestiture related 246 452 378 600 (Gains)/losses on securities 21 431 60 411 IPR&D impairments - 194 - 194 Other 27 - 27 - Tax Adjustments Tax impact on special item adjustments 2 (321) (437) 994 (1,293) Tax legislation and other tax related (214) (65) (202) (47) Adjusted Net Earnings , after tax $6,699 $6,840 $13,405 $13,420 Average shares outstanding (Diluted) 2,419.1 2,422.0 2,423.3 2,428.5 Adjusted net earnings per share (Diluted) $2.77 $2.82 $5.53 $5.53 Operational adjusted net earnings per share (Diluted) $2.71 $5.52 Notes: 1 2 Second Quarter Six Months Ended In fiscal 2023, the company completed a prioritization of its research and development (R&D) investment within the Innovative Medicine segment to focus on the most promising medicines with the greatest benefit to patients. This resulted in the exit of certain programs within therapeutic areas. The R&D program exits were primarily in infectious diseases and vaccines including the discontinuation of its respiratory syncytial virus (RSV) adult vaccine program, hepatitis and HIV development. The restructuring income of $63 million in the fiscal second quarter of 2024 ($81 million expense Q2 2024 YTD) included asset divestments and the termination of partnered and non-partnered program costs and asset impairments. This program was completed in Q4 2024. In fiscal 2023, the company initiated a restructuring program of its Orthopaedics franchise within the MedTech segment to streamline operations by exiting certain markets, product lines and distribution network arrangements. The restructuring expenses of $50 million in the fiscal second quarter of 2025 ($105 million Q2 2025 YTD) and $52 million in the fiscal second quarter of 2024 ($79 million Q2 2024 YTD) includes costs related to market and product exits. In fiscal 2025, the company initiated a restructuring program of its Surgery franchise within the MedTech segment to simplify and focus operations by exiting certain non-strategic product lines and optimize select sites across the network. Restructuring expenses of $29 million were recorded in the fiscal second quarter of 2025. The tax impact related to special item adjustments reflects the current and deferred income taxes associated with the above pre-tax special items in arriving at adjusted earnings. -- 11 of 22 -- Johnson & Johnson and Subsidiaries Reconciliation of Non-GAAP Financial Measure Innovative Medicine MedTech Total WW As Reported 4.9% 7.3% 5.8% U.S. 7.6% 8.0% 7.8% International 1.0% 6.7% 3.2% WW Currency 1.1 1.2 1.2 U.S. - - - International 2.6 2.6 2.6 WW Operational 3.8% 6.1% 4.6% U.S. 7.6% 8.0% 7.8% International (1.6)% 4.1% 0.6% Shockwave (2.2) (0.8) U.S. (3.5) (1.1) International (0.9) (0.3) Caplyta (1.4) (0.9) U.S. (2.4) (1.7) International 0.0 0.0 All Other Acquisitions and Divestitures (A&D) 0.0 0.2 0.1 U.S. 0.0 0.2 0.0 International 0.0 0.2 0.1 WW Adjusted Operational Ex A&D 2.4% 4.1% 3.0% U.S. 5.2% 4.7% 5.0% International (1.6)% 3.4% 0.4% Adjusted Operational Sales Growth SECOND QUARTER 2025 ACTUAL vs. 2024 ACTUAL Segments Note: Percentages are based on actual, non-rounded figures and may not sum -- 12 of 22 -- Johnson & Johnson and Subsidiaries Reconciliation of Non-GAAP Financial Measure Innovative Medicine MedTech Total WW As Reported 3.6% 5.0% 4.1% U.S. 7.0% 6.6% 6.9% International (0.9)% 3.3% 0.7% WW Currency (0.4) (0.1) (0.3) U.S. - - - International (0.8) (0.3) (0.7) WW Operational 4.0% 5.1% 4.4% U.S. 7.0% 6.6% 6.9% International (0.1)% 3.6% 1.4% Shockwave (2.7) (1.0) U.S. (4.3) (1.5) International (1.1) (0.5) Caplyta (0.8) (0.5) U.S. (1.3) (0.9) International 0.0 0.0 All Other Acquisitions and Divestitures (A&D) 0.1 0.3 0.2 U.S. 0.0 0.5 0.2 International 0.2 0.2 0.2 WW Adjusted Operational Ex A&D 3.3% 2.7% 3.1% U.S. 5.7% 2.8% 4.7% International 0.1% 2.7% 1.1% Note: Percentages are based on actual, non-rounded figures and may not sum Adjusted Operational Sales Growth SIX MONTHS 2025 ACTUAL vs. 2024 ACTUAL Segments -- 13 of 22 -- REPORTED SALES vs. PRIOR PERIOD ($MM) REPORTED SALES vs. PRIOR PERIOD ($MM) SECOND QUARTER SIX MONTHS INNOVATIVE MEDICINE SEGMENT (2) 2025 2024 Reported Operational (1) Currency 2025 2024 Reported Operational (1) Currency ONCOLOGY US 3,385 $ 2,636 28.4% 28.4% - 6,398 $ 5,019 27.5% 27.5% - Intl 2,928 2,455 19.3% 15.7% 3.6% 5,592 4,885 14.5% 15.1% -0.6% WW 6,312 5,090 24.0% 22.3% 1.7% 11,990 9,904 21.1% 21.3% -0.2% CARVYKTI US 358 167 * * - 676 307 * * - Intl 81 20 * * * 132 36 * * * WW 439 186 * * * 808 343 * * * DARZALEX US 2,017 1,641 23.0% 23.0% - 3,846 3,105 23.9% 23.9% - Intl 1,521 1,237 23.0% 19.6% 3.4% 2,930 2,465 18.9% 19.7% -0.8% WW 3,539 2,878 23.0% 21.5% 1.5% 6,776 5,570 21.7% 22.0% -0.3% ERLEADA US 378 318 18.6% 18.6% - 670 603 11.0% 11.0% - Intl 530 418 27.0% 22.8% 4.2% 1,009 822 22.9% 23.0% -0.1% WW 908 736 23.4% 21.0% 2.4% 1,679 1,425 17.8% 17.9% -0.1% IMBRUVICA US 239 246 -2.7% -2.7% - 474 511 -7.3% -7.3% - Intl 496 525 -5.4% -8.4% 3.0% 970 1,043 -6.9% -6.3% -0.6% WW 735 770 -4.5% -6.6% 2.1% 1,444 1,554 -7.0% -6.6% -0.4% RYBREVANT / LAZCLUZE (3) US 139 52 * * - 252 88 * * - Intl 41 17 * * * 69 28 * * * WW 179 69 * * * 320 116 * * * TALVEY US 82 59 38.0% 38.0% - 150 109 36.7% 36.7% - Intl 24 9 * * * 42 17 * * * WW 106 69 55.0% 54.3% 0.7% 192 127 52.0% 52.4% -0.4% TECVAYLI US 114 104 8.2% 8.2% - 219 205 6.6% 6.6% - Intl 52 30 74.8% 72.0% 2.8% 98 63 56.0% 58.4% -2.4% WW 166 135 23.1% 22.4% 0.7% 317 268 18.2% 18.7% -0.5% ZYTIGA / abiraterone acetate US 6 11 -38.9% -38.9% - 13 20 -31.9% -31.9% - Intl 139 154 -9.8% -13.3% 3.5% 257 326 -21.1% -21.3% 0.2% WW 145 165 -11.6% -14.9% 3.3% 270 346 -21.7% -21.9% 0.2% OTHER ONCOLOGY US 50 37 36.9% 36.9% - 97 70 39.8% 39.8% - Intl 42 45 -8.7% -12.3% 3.6% 84 86 -2.5% -1.8% -0.7% WW 93 83 11.7% 9.7% 2.0% 182 156 16.4% 16.8% -0.4% See footnotes at end of schedule % Change % Change -- 14 of 22 -- REPORTED SALES vs. PRIOR PERIOD ($MM) REPORTED SALES vs. PRIOR PERIOD ($MM) SECOND QUARTER SIX MONTHS 2025 2024 Reported Operational (1) Currency 2025 2024 Reported Operational (1) Currency IMMUNOLOGY US 2,505 $ 2,978 -15.9% -15.9% - 4,701 $ 5,431 -13.4% -13.4% - Intl 1,489 1,744 -14.6% -16.2% 1.6% 2,999 3,538 -15.2% -13.8% -1.4% WW 3,993 4,722 -15.4% -16.0% 0.6% 7,700 8,969 -14.1% -13.6% -0.5% REMICADE US 283 231 22.5% 22.5% - 597 497 20.1% 20.1% - US Exports (4) 34 35 -2.6% -2.6% - 44 62 -28.7% -28.7% - Intl 138 127 8.6% 8.8% -0.2% 281 268 4.8% 7.7% -2.9% WW 455 393 15.9% 15.9% 0.0% 922 827 11.5% 12.4% -0.9% SIMPONI / SIMPONI ARIA US 305 267 14.0% 14.0% - 597 521 14.4% 14.4% - Intl 387 270 43.1% 40.8% 2.3% 753 569 32.2% 35.0% -2.8% WW 690 537 28.6% 27.5% 1.1% 1,349 1,091 23.7% 25.1% -1.4% STELARA US 1,078 1,855 -41.9% -41.9% - 2,059 3,251 -36.7% -36.7% - Intl 575 1,030 -44.2% -45.6% 1.4% 1,219 2,085 -41.5% -40.6% -0.9% WW 1,653 2,885 -42.7% -43.2% 0.5% 3,278 5,336 -38.6% -38.2% -0.4% TREMFYA US 796 589 35.2% 35.2% - 1,395 1,098 27.1% 27.1% - Intl 391 317 23.2% 20.5% 2.7% 747 616 21.2% 22.4% -1.2% WW 1,186 906 31.0% 30.1% 0.9% 2,142 1,714 25.0% 25.4% -0.4% OTHER IMMUNOLOGY US 8 2 * * - 9 2 * * - Intl 0 0 - - - 0 0 - - - WW 8 2 * * - 9 2 * * - NEUROSCIENCE US 1,377 1,102 24.9% 24.9% - 2,345 2,156 8.7% 8.7% - Intl 674 679 -0.8% -2.6% 1.8% 1,353 1,428 -5.2% -4.1% -1.1% WW 2,051 1,782 15.1% 14.4% 0.7% 3,698 3,585 3.2% 3.6% -0.4% CAPLYTA (5) US 211 - * * - 211 - * * - Intl - - - - - - - - - - WW 211 - * * - 211 - * * - CONCERTA / Methylphenidate US 24 34 -27.7% -27.7% - 62 75 -16.6% -16.6% - Intl 139 129 7.5% 7.0% 0.5% 249 265 -6.0% -4.4% -1.6% WW 164 163 0.2% -0.2% 0.4% 312 340 -8.3% -7.1% -1.2% INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA US 732 784 -6.7% -6.7% - 1,357 1,549 -12.4% -12.4% - Intl 260 269 -3.5% -5.1% 1.6% 537 561 -4.2% -3.1% -1.1% WW 992 1,054 -5.9% -6.3% 0.4% 1,895 2,110 -10.2% -9.9% -0.3% SPRAVATO US 366 226 61.1% 61.1% - 642 417 53.7% 53.7% - Intl 50 44 12.8% 11.0% 1.8% 93 78 18.1% 20.1% -2.0% WW 414 271 53.3% 53.0% 0.3% 734 496 48.1% 48.4% -0.3% OTHER NEUROSCIENCE US 45 57 -23.5% -23.5% - 73 115 -37.0% -37.0% - Intl 226 237 -4.7% -7.6% 2.9% 474 524 -9.5% -8.8% -0.7% WW 270 294 -8.4% -10.7% 2.3% 547 639 -14.4% -13.9% -0.5% See footnotes at end of schedule % Change % Change -- 15 of 22 -- REPORTED SALES vs. PRIOR PERIOD ($MM) REPORTED SALES vs. PRIOR PERIOD ($MM) SECOND QUARTER SIX MONTHS 2025 2024 Reported Operational (1) Currency 2025 2024 Reported Operational (1) Currency PULMONARY HYPERTENSION US 799 $ 743 7.6% 7.6% - 1,543 $ 1,509 2.3% 2.3% - Intl 314 296 5.8% 2.8% 3.0% 595 579 2.6% 3.0% -0.4% WW 1,113 1,039 7.1% 6.2% 0.9% 2,138 2,088 2.4% 2.5% -0.1% OPSUMIT / OPSYNVI US 403 376 6.9% 6.9% - 766 732 4.6% 4.6% - Intl 180 171 5.4% 2.1% 3.3% 339 340 -0.3% -0.2% -0.1% WW 582 548 6.4% 5.4% 1.0% 1,104 1,072 3.0% 3.1% -0.1% UPTRAVI US 382 349 9.4% 9.4% - 747 741 0.8% 0.8% - Intl 94 76 22.4% 19.8% 2.6% 180 152 17.9% 18.7% -0.8% WW 476 426 11.7% 11.3% 0.4% 927 894 3.7% 3.8% -0.1% OTHER PULMONARY HYPERTENSION US 16 17 -12.4% -12.4% - 31 35 -12.6% -12.6% - Intl 40 49 -18.5% -21.3% 2.8% 77 88 -12.4% -12.1% -0.3% WW 55 67 -16.9% -19.0% 2.1% 107 123 -12.5% -12.3% -0.2% INFECTIOUS DISEASES US 320 334 -4.3% -4.3% - 635 658 -3.6% -3.6% - Intl 484 631 -23.4% -26.8% 3.4% 971 1,128 -13.9% -14.1% 0.2% WW 803 965 -16.8% -19.0% 2.2% 1,605 1,786 -10.1% -10.2% 0.1% EDURANT / rilpivirine US 6 8 -25.4% -25.4% - 14 16 -13.6% -13.6% - Intl 354 288 23.0% 16.7% 6.3% 704 603 16.7% 15.6% 1.1% WW 360 297 21.6% 15.5% 6.1% 718 620 15.9% 14.9% 1.0% PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA US 312 321 -3.0% -3.0% - 617 635 -2.9% -2.9% - Intl 85 117 -27.0% -29.4% 2.4% 183 221 -17.2% -15.8% -1.4% WW 396 438 -9.4% -10.0% 0.6% 799 856 -6.6% -6.3% -0.3% OTHER INFECTIOUS DISEASES US 2 5 -51.8% -51.8% - 4 7 -37.4% -37.4% - Intl 45 227 -80.5% -80.6% 0.1% 84 304 -72.5% -72.1% -0.4% WW 47 233 -79.8% -79.9% 0.1% 88 311 -71.7% -71.3% -0.4% CARDIOVASCULAR / METABOLISM / OTHER US 776 717 8.2% 8.2% - 1,631 1,348 21.0% 21.0% - Intl 154 176 -12.3% -13.2% 0.9% 312 373 -16.2% -14.3% -1.9% WW 930 892 4.2% 4.0% 0.2% 1,943 1,721 12.9% 13.3% -0.4% XARELTO US 621 587 5.6% 5.6% - 1,311 1,105 18.6% 18.6% - Intl - - - - - - - - - - WW 621 587 5.6% 5.6% - 1,311 1,105 18.6% 18.6% - OTHER US 155 129 20.0% 20.0% - 320 243 31.6% 31.6% - Intl 154 176 -12.3% -13.2% 0.9% 312 373 -16.2% -14.3% -1.9% WW 309 305 1.4% 0.9% 0.5% 632 616 2.7% 3.9% -1.2% TOTAL INNOVATIVE MEDICINE US 9,161 8,510 7.6% 7.6% - 17,253 16,122 7.0% 7.0% - Intl 6,041 5,980 1.0% -1.6% 2.6% 11,822 11,930 -0.9% -0.1% -0.8% WW 15,202 $ 14,490 4.9% 3.8% 1.1% 29,075 $ 28,052 3.6% 4.0% -0.4% See footnotes at end of schedule % Change % Change -- 16 of 22 -- REPORTED SALES vs. PRIOR PERIOD ($MM) REPORTED SALES vs. PRIOR PERIOD ($MM) SECOND QUARTER SIX MONTHS MEDTECH SEGMENT (2) 2025 2024 Reported Operational (1) Currency 2025 2024 Reported Operational (1) Currency CARDIOVASCULAR US 1,364 $ 1,119 21.9% 21.9% - 2,625 $ 2,144 22.4% 22.4% - Intl 948 753 25.9% 22.9% 3.0% 1,790 1,534 16.7% 16.7% 0.0% WW 2,313 1,873 23.5% 22.3% 1.2% 4,416 3,679 20.0% 20.0% 0.0% ELECTROPHYSIOLOGY US 741 705 5.1% 5.1% - 1,425 1,397 2.0% 2.0% - Intl 728 618 17.8% 15.2% 2.6% 1,366 1,270 7.6% 7.8% -0.2% WW 1,468 1,323 11.0% 9.8% 1.2% 2,791 2,667 4.7% 4.7% 0.0% ABIOMED US 360 309 16.6% 16.6% - 699 612 14.2% 14.2% - Intl 89 72 25.0% 18.4% 6.6% 170 139 22.4% 20.9% 1.5% WW 448 379 18.2% 16.9% 1.3% 868 750 15.7% 15.5% 0.2% SHOCKWAVE (6) US 233 77 * * - 439 77 * * - Intl 58 0 * * * 110 0 * * * WW 292 77 * * * 550 77 * * - OTHER CARDIOVASCULAR US 31 29 5.4% 5.4% - 63 59 6.3% 6.3% - Intl 72 64 13.4% 11.6% 1.8% 144 126 14.2% 14.5% -0.3% WW 104 93 10.8% 9.7% 1.1% 207 185 11.7% 11.8% -0.1% ORTHOPAEDICS US 1,420 1,422 -0.2% -0.2% - 2,804 2,870 -2.3% -2.3% - Intl 885 890 -0.5% -4.0% 3.5% 1,742 1,782 -2.2% -2.4% 0.2% WW 2,305 2,312 -0.3% -1.6% 1.3% 4,546 4,652 -2.3% -2.3% 0.0% HIPS US 271 265 2.1% 2.1% - 534 535 -0.2% -0.2% - Intl 150 152 -1.0% -4.3% 3.3% 296 304 -2.5% -2.6% 0.1% WW 421 417 1.0% -0.2% 1.2% 830 839 -1.1% -1.1% 0.0% KNEES US 226 230 -1.9% -1.9% - 457 472 -3.1% -3.1% - Intl 164 163 0.0% -2.9% 2.9% 322 323 -0.5% -0.4% -0.1% WW 389 394 -1.1% -2.3% 1.2% 778 795 -2.0% -2.0% 0.0% TRAUMA US 501 498 0.7% 0.7% - 1,003 1,002 0.1% 0.1% - Intl 267 260 2.2% -1.5% 3.7% 537 521 2.9% 2.8% 0.1% WW 768 759 1.2% -0.1% 1.3% 1,540 1,524 1.1% 1.0% 0.1% SPINE, SPORTS & OTHER US 422 430 -1.7% -1.7% - 810 862 -6.0% -6.0% - Intl 305 314 -2.7% -6.4% 3.7% 588 634 -7.2% -7.7% 0.5% WW 727 743 -2.1% -3.7% 1.6% 1,398 1,495 -6.5% -6.7% 0.2% See footnotes at end of schedule % Change % Change -- 17 of 22 -- REPORTED SALES vs. PRIOR PERIOD ($MM) REPORTED SALES vs. PRIOR PERIOD ($MM) SECOND QUARTER SIX MONTHS 2025 2024 Reported Operational (1) Currency 2025 2024 Reported Operational (1) Currency SURGERY US 1,043 $ 995 4.8% 4.8% - 2,045 $ 1,982 3.2% 3.2% - Intl 1,512 1,493 1.3% -0.2% 1.5% 2,906 2,922 -0.5% 0.3% -0.8% WW 2,555 2,488 2.7% 1.8% 0.9% 4,951 4,904 1.0% 1.5% -0.5% ADVANCED US 477 466 2.2% 2.2% - 934 912 2.4% 2.4% - Intl 687 675 1.9% 0.2% 1.7% 1,303 1,316 -1.0% -0.4% -0.6% WW 1,164 1,141 2.0% 1.0% 1.0% 2,237 2,228 0.4% 0.8% -0.4% GENERAL US 567 528 7.2% 7.2% - 1,111 1,070 3.8% 3.8% - Intl 825 818 0.9% -0.6% 1.5% 1,603 1,606 -0.1% 0.8% -0.9% WW 1,391 1,346 3.3% 2.5% 0.8% 2,714 2,676 1.4% 2.0% -0.6% VISION US 557 523 6.5% 6.5% - 1,123 1,070 4.9% 4.9% - Intl 813 763 6.5% 3.4% 3.1% 1,526 1,473 3.6% 3.7% -0.1% WW 1,369 1,285 6.5% 4.6% 1.9% 2,648 2,543 4.1% 4.2% -0.1% CONTACT LENSES / OTHER US 429 409 4.8% 4.8% - 881 847 3.9% 3.9% - Intl 536 509 5.4% 1.4% 4.0% 1,003 981 2.3% 1.9% 0.4% WW 965 918 5.1% 2.9% 2.2% 1,884 1,828 3.1% 2.8% 0.3% SURGICAL US 128 113 12.6% 12.6% - 242 223 8.5% 8.5% - Intl 277 254 8.8% 7.3% 1.5% 523 492 6.2% 7.2% -1.0% WW 403 367 9.9% 8.9% 1.0% 764 715 6.9% 7.6% -0.7% TOTAL MEDTECH US 4,383 4,059 8.0% 8.0% - 8,596 8,067 6.6% 6.6% - Intl 4,158 3,898 6.7% 4.1% 2.6% 7,965 7,711 3.3% 3.6% -0.3% WW 8,541 $ 7,957 7.3% 6.1% 1.2% 16,561 $ 15,778 5.0% 5.1% -0.1% * Percentage greater than 100% or not meaningful (1) Operational growth excludes the effect of translational currency (2) Unaudited (3) Includes the sales of RYBREVANT and RYBREVANT + LAZCLUZE (4) Reported as U.S. sales (5) Acquired with Intra-Cellular Therapies on April 2, 2025 (6) Acquired on May 31, 2024 Note: Columns and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely % Change % Change -- 18 of 22 -- Innovative Medicine Second Quarter June 29, 2025 GAAP Intangible asset amortization Litigation related Restructuring related Acquisition, integration and divestiture related (Loss)/gain on securities Tax legislation and other tax related Other Second Quarter June 29, 2025 Non-GAAP Cost of products sold 3,978 $ (785) (13) 3,180 Selling, marketing and admin expenses 2,789 2,789 Research and development expense 2,869 2,869 Other segment items 14 69 (207) 8 (13) (129) Adjusted Income Before Tax by Segment 5,552 785 (69) - 220 (8) - 13 6,493 MedTech Second Quarter June 29, 2025 GAAP Intangible asset amortization Litigation related Restructuring related Acquisition, integration and divestiture related (Loss)/gain on securities Tax legislation and other tax related Other Second Quarter June 29, 2025 Non-GAAP Cost of products sold 3,638 $ (482) (15) 1 3,142 Selling, marketing and admin expenses 2,862 2,862 Research and development expense 647 43 690 Other segment items 190 (83) (64) (53) (29) (14) (53) Adjusted Income Before Tax by Segment 1,204 482 83 79 9 29 - 14 1,900 Expenses not allocated to segments Second Quarter June 29, 2025 GAAP Intangible asset amortization Litigation related Restructuring related Acquisition, integration and divestiture related (Loss)/gain on securities Tax legislation and other tax related Other Second Quarter June 29, 2025 Non-GAAP Cost of products sold 12 $ 12 Selling, marketing and admin expenses 238 238 Research and development expense - - Other segment items 15 (43) (17) (45) Adjusted Income Before Tax by Segment (265) - 43 - 17 - - - (205) Johnson & Johnson Consolidated Second Quarter June 29, 2025 GAAP Intangible asset amortization Litigation related Restructuring related Acquisition, integration and divestiture related (Loss)/gain on securities Tax legislation and other tax related Other Second Quarter June 29, 2025 Non-GAAP Cost of products sold 7,628 $ (1,267) (15) (12) 6,334 Selling, marketing and admin expenses 5,889 5,889 Research and development expense 3,516 43 3,559 Other (Income) / Expense 107 (57) (277) (21) (27) (275) In-process research and development impairments - - Interest (Income)/Expense 48 48 Restructuring 64 (64) - Adjusted Income Before Tax 6,491 1,267 57 79 246 21 - 27 8,188 Provision for taxes on income 954 222 9 13 72 5 214 - 1,489 Net Earnings 5,537 1,045 48 66 174 16 (214) 27 6,699 Johnson & Johnson and Subsidiaries GAAP to Non-GAAP Reconciliation $ in Millions Quarter to Date -- 19 of 22 -- Innovative Medicine Second Quarter June 30, 2024 GAAP Intangible asset amortization Litigation related In-process research and development impairments Restructuring related Acquisition, integration and divestiture related (Loss)/gain on securities Medical Device Regulation COVID-19 Vaccine Related Costs Tax legislation and other tax related Second Quarter June 30, 2024 Non-GAAP Cost of products sold 3,603 $ (694) (4) 2,905 Selling, marketing and admin expenses 2,665 2,665 Research and development expense 2,722 (10) 2,712 Other segment items 41 (43) (194) 63 (1) (70) (50) (254) Adjusted Income Before Tax by Segment 5,459 694 43 194 (63) 1 70 - 64 - 6,462 MedTech Second Quarter June 30, 2024 GAAP Intangible asset amortization Litigation related In-process research and development impairments Restructuring related Acquisition, integration and divestiture related (Loss)/gain on securities Medical Device Regulation COVID-19 Vaccine Related Costs Tax legislation and other tax related Second Quarter June 30, 2024 Non-GAAP Cost of products sold 3,248 $ (412) (2) (50) (30) 2,754 Selling, marketing and admin expenses 2,671 (5) 2,666 Research and development expense 718 (15) (33) 670 Other segment items 231 4 (50) (344) (22) (181) Adjusted Income Before Tax by Segment 1,089 412 (4) - 52 409 22 68 - - 2,048 Expenses not allocated to segments Second Quarter June 30, 2024 GAAP Intangible asset amortization Litigation related In-process research and development impairments Restructuring related Acquisition, integration and divestiture related (Loss)/gain on securities Medical Device Regulation COVID-19 Vaccine Related Costs Tax legislation and other tax related Second Quarter June 30, 2024 Non-GAAP Cost of products sold 18 $ 18 Selling, marketing and admin expenses 345 345 Research and development expense - - Other segment items 437 (313) (42) (339) (257) Adjusted Income Before Tax by Segment (800) - 313 - - 42 339 - - - (106) Johnson & Johnson Consolidated Second Quarter June 30, 2024 GAAP Intangible asset amortization Litigation related In-process research and development impairments Restructuring related Acquisition, integration and divestiture related (Loss)/gain on securities Medical Device Regulation COVID-19 Vaccine Related Costs Tax legislation and other tax related Second Quarter June 30, 2024 Non-GAAP Cost of products sold 6,869 $ (1,106) (2) (50) (30) (4) 5,677 Selling, marketing and admin expenses 5,681 (5) 5,676 Research and development expense 3,440 (15) (33) (10) 3,382 Other (Income) / Expense 653 (352) (387) (431) (50) (567) In-process research and development impairments 194 (194) - Interest (Income)/Expense (125) (125) Restructuring (13) 13 - Adjusted Income Before Tax 5,748 1,106 352 194 (11) 452 431 68 64 - 8,404 Provision for taxes on income 1,062 156 70 43 (6) 125 21 14 14 65 1,564 Net Earnings 4,686 950 282 151 (5) 327 410 54 50 (65) 6,840 Johnson & Johnson and Subsidiaries GAAP to Non-GAAP Reconciliation $ in Millions Quarter to Date -- 20 of 22 -- Year to Date Innovative Medicine Six Months June 29, 2025 GAAP Intangible asset amortization Litigation related Restructuring related Acquisition, integration and divestiture related (Loss)/gain on securities Tax legislation and other tax related Other Six Months June 29, 2025 Non-GAAP Cost of products sold 7,998 $ (1,434) (13) 6,551 Selling, marketing and admin expenses 5,050 5,050 Research and development expense 5,417 5,417 Other segment items (152) 69 (227) (10) (13) (333) Adjusted Income Before Tax by Segment 10,762 1,434 (69) - 240 10 - 13 12,390 MedTech Six Months June 29, 2025 GAAP Intangible asset amortization Litigation related Restructuring related Acquisition, integration and divestiture related (Loss)/gain on securities Tax legislation and other tax related Other Six Months June 29, 2025 Non-GAAP Cost of products sold 6,964 $ (953) (23) (51) 5,937 Selling, marketing and admin expenses 5,518 5,518 Research and development expense 1,324 37 1,361 Other segment items 130 (83) (111) (107) (50) (14) (235) Adjusted Income Before Tax by Segment 2,625 953 83 134 121 50 - 14 3,980 Expenses not allocated to segments Six Months June 29, 2025 GAAP Intangible asset amortization Litigation related Restructuring related Acquisition, integration and divestiture related (Loss)/gain on securities Tax legislation and other tax related Other Six Months June 29, 2025 Non-GAAP Cost of products sold 23 $ 23 Selling, marketing and admin expenses 433 433 Research and development expense - - Other segment items (7,191) 6,923 (17) (285) Adjusted Income Before Tax by Segment 6,735 - (6,923) - 17 - - - (171) Johnson & Johnson Consolidated Six Months June 29, 2025 GAAP Intangible asset amortization Litigation related Restructuring related Acquisition, integration and divestiture related (Loss)/gain on securities Tax legislation and other tax related Other Six Months June 29, 2025 Non-GAAP Cost of products sold 14,985 $ (2,387) (23) (64) 12,511 Selling, marketing and admin expenses 11,001 11,001 Research and development expense 6,741 37 6,778 Other (Income) / Expense (7,214) 6,909 (30) (351) (60) (27) (773) In-process research and development impairments - - Interest (Income)/Expense (80) (80) Restructuring 81 (81) - Adjusted Income Before Tax 20,122 2,387 (6,909) 134 378 60 - 27 16,199 Provision for taxes on income 3,586 410 (1,544) 24 102 14 202 2,794 Net Earnings 16,536 1,977 (5,365) 110 276 46 (202) 27 13,405 Johnson & Johnson and Subsidiaries GAAP to Non-GAAP Reconciliation $ in Millions -- 21 of 22 -- Innovative Medicine Six Months June 30, 2024 GAAP Intangible asset amortization Litigation related In-process research and development impairments Restructuring related Acquisition, integration and divestiture related (Loss)/gain on securities Medical Device Regulation COVID-19 Vaccine Related Costs Tax legislation and other tax related Six Months June 30, 2024 Non-GAAP Cost of products sold 6,973 $ (1,392) (6) 5,575 Selling, marketing and admin expenses 5,103 5,103 Research and development expense 5,618 (17) 5,601 Other segment items (70) (43) (194) (81) (48) (15) (50) (501) Adjusted Income Before Tax by Segment 10,428 1,392 43 194 81 48 15 - 73 - 12,274 MedTech Six Months June 30, 2024 GAAP Intangible asset amortization Litigation related In-process research and development impairments Restructuring related Acquisition, integration and divestiture related (Loss)/gain on securities Medical Device Regulation COVID-19 Vaccine Related Costs Tax legislation and other tax related Six Months June 30, 2024 Non-GAAP Cost of products sold 6,368 $ (792) (9) (50) (50) 5,467 Selling, marketing and admin expenses 5,253 (9) 5,244 Research and development expense 1,364 (33) (60) 1,271 Other segment items 184 4 (70) (387) (44) (313) Adjusted Income Before Tax by Segment 2,609 792 (4) - 79 470 44 119 - - 4,109 Expenses not allocated to segments Six Months June 30, 2024 GAAP Intangible asset amortization Litigation related In-process research and development impairments Restructuring related Acquisition, integration and divestiture related (Loss)/gain on securities Medical Device Regulation COVID-19 Vaccine Related Costs Tax legislation and other tax related Six Months June 30, 2024 Non-GAAP Cost of products sold 39 $ 39 Selling, marketing and admin expenses 582 582 Research and development expense - - Other segment items 2,954 (3,039) (82) (352) (519) Adjusted Income Before Tax by Segment (3,575) - 3,039 - - 82 352 - - - (102) Johnson & Johnson Consolidated Six Months June 30, 2024 GAAP Intangible asset amortization Litigation related In-process research and development impairments Restructuring related Acquisition, integration and divestiture related (Loss)/gain on securities Medical Device Regulation COVID-19 Vaccine Related Costs Tax legislation and other tax related Six Months June 30, 2024 Non-GAAP Cost of products sold 13,380 $ (2,184) (9) (50) (50) (6) 11,081 Selling, marketing and admin expenses 10,938 (9) 10,929 Research and development expense 6,982 (33) (60) (17) 6,872 Other (Income) / Expense 3,057 (3,078) (517) (411) (50) (999) In-process research and development impairments 194 (194) - Interest (Income)/Expense (334) (334) Restructuring 151 (151) - Adjusted Income Before Tax 9,462 2,184 3,078 194 160 600 411 119 73 - 16,281 Provision for taxes on income 1,521 304 697 43 33 163 14 23 16 47 2,861 Net Earnings 7,941 1,880 2,381 151 127 437 397 96 57 (47) 13,420 Johnson & Johnson and Subsidiaries GAAP to Non-GAAP Reconciliation $ in Millions Year to Date -- 22 of 22 --